These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 19924503)

  • 1. Psoriasis during interferon beta treatment for multiple sclerosis.
    La Mantia L; Capsoni F
    Neurol Sci; 2010 Jun; 31(3):337-9. PubMed ID: 19924503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Simvastatin treatment in patients with relapsing-remitting multiple sclerosis receiving interferon beta 1a: a double-blind randomized controlled trial.
    Togha M; Karvigh SA; Nabavi M; Moghadam NB; Harirchian MH; Sahraian MA; Enzevaei A; Nourian A; Ghanaati H; Firouznia K; Jannati A; Shekiba M
    Mult Scler; 2010 Jul; 16(7):848-54. PubMed ID: 20488825
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interferon beta-1b is effective in Japanese RRMS patients: a randomized, multicenter study.
    Saida T; Tashiro K; Itoyama Y; Sato T; Ohashi Y; Zhao Z;
    Neurology; 2005 Feb; 64(4):621-30. PubMed ID: 15728282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interferon beta-1b (Extavia) for multiple sclerosis.
    Med Lett Drugs Ther; 2010 Nov; 52(1350):86-7. PubMed ID: 21045760
    [No Abstract]   [Full Text] [Related]  

  • 5. Cutaneous Adverse Events Associated with Interferon-β Treatment of Multiple Sclerosis.
    Kolb-Mäurer A; Goebeler M; Mäurer M
    Int J Mol Sci; 2015 Jul; 16(7):14951-60. PubMed ID: 26147425
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of systemic sclerosis in a female patient with multiple sclerosis following beta interferon treatment.
    Powell A; Myles ML; Yacyshyn E
    Clin Rheumatol; 2008 Nov; 27(11):1467-8. PubMed ID: 18704546
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relapsing-remitting multiple sclerosis and chronic idiopathic neutropenia: a challenging combination.
    Münzel EJ; Wimperis JZ; Williams A
    BMJ Case Rep; 2013 Feb; 2013():. PubMed ID: 23417376
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fumaric acid esters in psoriasis and multiple sclerosis.
    Zecca C; Caporro M; Adami M; Mainetti C; Gobbi C
    Clin Exp Dermatol; 2014 Jun; 39(4):488-91. PubMed ID: 24779791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical characteristics of responders to interferon therapy for relapsing MS.
    Waubant E; Vukusic S; Gignoux L; Dubief FD; Achiti I; Blanc S; Renoux C; Confavreux C
    Neurology; 2003 Jul; 61(2):184-9. PubMed ID: 12874396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A man with erythematosquamous plaques].
    Weng YC; Bruynzeel F
    Ned Tijdschr Geneeskd; 2021 Feb; 165():. PubMed ID: 33651510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.
    Wynn D; Kaufman M; Montalban X; Vollmer T; Simon J; Elkins J; O'Neill G; Neyer L; Sheridan J; Wang C; Fong A; Rose JW;
    Lancet Neurol; 2010 Apr; 9(4):381-90. PubMed ID: 20163990
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Arthritic psoriasis during natalizumab treatment: a case report and review of the literature.
    Vacchiano V; Foschi M; Sabattini L; Scandellari C; Lugaresi A
    Neurol Sci; 2018 Jan; 39(1):181-183. PubMed ID: 28905124
    [No Abstract]   [Full Text] [Related]  

  • 13. Interferon beta related pulmonary arterial hypertension; an emerging worrying entity?
    Govern EM; Judge EP; Kavanagh E; Gaine S; Lynch T
    Mult Scler Relat Disord; 2015 May; 4(3):284-6. PubMed ID: 26008947
    [No Abstract]   [Full Text] [Related]  

  • 14. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
    Nikfar S; Rahimi R; Abdollahi M
    Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term adherence to interferon beta therapy in relapsing-remitting multiple sclerosis.
    Portaccio E; Zipoli V; Siracusa G; Sorbi S; Amato MP
    Eur Neurol; 2008; 59(3-4):131-5. PubMed ID: 18057899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Favorable outcome of interferon-beta associated thrombotic microangiopathy following treatment with corticosteroids, plasma exchange and rituximab: A case report.
    Gerischer LM; Siebert E; Janke O; Jungehuelsing GJ; Ruprecht K
    Mult Scler Relat Disord; 2016 Nov; 10():63-65. PubMed ID: 27919500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis.
    Hauser SL; Bar-Or A; Comi G; Giovannoni G; Hartung HP; Hemmer B; Lublin F; Montalban X; Rammohan KW; Selmaj K; Traboulsee A; Wolinsky JS; Arnold DL; Klingelschmitt G; Masterman D; Fontoura P; Belachew S; Chin P; Mairon N; Garren H; Kappos L;
    N Engl J Med; 2017 Jan; 376(3):221-234. PubMed ID: 28002679
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The challenges of measuring disability accumulation in relapsing-remitting multiple sclerosis: evidence from interferon beta treatments.
    Kieseier BC
    Expert Rev Neurother; 2014 Jan; 14(1):105-20. PubMed ID: 24417500
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Voxel-wise magnetization transfer imaging study of effects of natalizumab and IFNβ-1a in multiple sclerosis.
    Zivadinov R; Dwyer MG; Hussein S; Carl E; Kennedy C; Andrews M; Hojnacki D; Heininen-Brown M; Willis L; Cherneva M; Bergsland N; Weinstock-Guttman B
    Mult Scler; 2012 Aug; 18(8):1125-34. PubMed ID: 22194217
    [TBL] [Abstract][Full Text] [Related]  

  • 20. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a.
    Gasperini C; Paolillo A; Giugni E; Galgani S; Bagnato F; Mainero C; Onesti E; Bastianello S; Pozzilli C
    Mult Scler; 2002 Apr; 8(2):119-23. PubMed ID: 11990868
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.